Drug intelligence / Profile preview

XeroDuo

Development stage: Preclinical
Lead developer: XeroThera
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Injectable

Overview

XeroDuo is an injectable nanoparticle-based drug delivery system developed by XeroThera. It is designed for the controlled and sustained delivery of two antibiotics to combat resistant superbugs and prevent infections. The product is currently in various stages of development and is not yet available for sale in the USA. Its primary intended application is for infection prevention, particularly in orthopedic surgeries.

Brand names: XeroDuo

Beyond the preview

Go deeper on XeroDuo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XeroDuo.

Explore the full profile